Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sterling/Yamanouchi joint venture

Executive Summary

Sterling's joint venture with the Japanese firm, to be known as Sterling-Yamanouchi, will commercialize Sterling's ethical drugs in Japan. Under the agreement, Yamanouchi will be the exclusive distributor of the joint venture's products in Japan. The venture, which is subject to Japanese regulatory approval, will be co-owned by Sterling (51%) and Yamanouchi (49%). Sterling said its existing licenses in Japan will remain intact and its OTC and consumer products will continue to be marketed through Sterling-Winthrop.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS009196

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel